Open AccessAnti-RAGE and A Immunoglobulin Levels Are Related to Dementia Level and Cognitive Performance
Author(s) -
J. S. Wilson,
Shyamala Mruthinti,
Jerry J. Buccafusco,
Rosann Schade,
Max B. Mitchell,
Demetress Harrell,
Nidhi K. Gulati,
L. Stephen Miller
Publication year - 2009
Publication title -
the journals of gerontology series a
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.134
H-Index - 189
eISSN - 1758-535X
pISSN - 1079-5006
DOI - 10.1093/gerona/gln002
Subject(s) - repeatable battery for the assessment of neuropsychological status , rage (emotion) , medicine , analysis of variance , immunology , clinical dementia rating , dementia , cognitive decline , antibody , psychology , immunoglobulin g , cognition , neuropsychology , disease , psychiatry , neuroscience
Blood-based immunoglobulins (IgGs) may mark the presence of amyloid plaques characterizing the progression of Alzheimer's disease (AD). Previous studies suggest that anti-RAGE and anti-Abeta IgGs increase proportionately with accumulation of amyloid-beta (Abeta) peptides at receptor sites for advanced glycation end products (RAGE), within cortical areas of brain tissue. We assessed the relationship between these potential markers and an AD-type cognitive profile. We hypothesized that these specific IgG levels would be positively correlated with Clinical Dementia Rating (CDR) scores as well as index scores on the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) in domains associated with cortical function.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom